网红黑料

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention鈥�

Investigator

Torge Rempe

Status

Accepting Candidates

Ages

18 Years - 60 Years

Sexes

All

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Investigator

Torge Rempe

Status

Accepting Candidates

Ages

18 Years - 55 Years

Sexes

All

The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period

Investigator

Torge Rempe

Status

Accepting Candidates

Ages

12 Years - N/A

Sexes

All